The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Authors

  • Arianna Bertolani CERGAS (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Università Bocconi, Milan - Italy
  • Roberto Ravasio MA Provider, Milan - Italy https://orcid.org/0000-0002-5477-1957
  • Paola Raimondo MA Provider, Milan - Italy https://orcid.org/0000-0003-3316-4266
  • Claudio Jommi CERGAS (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Università Bocconi, Milan - Italy

DOI:

https://doi.org/10.33393/grhta.2022.2415

Keywords:

Clinical pathway, Costs, Eligibility, Follow-up, Organisational impact, PCSK9

Abstract

Background. Several health care services are required to get eligibility to PCSK9-inhibitors medicines and the follow-up of patients being treated. The ultimate goal is making prescriptions appropriate and monitoring the effects of these drugs. Some recent papers (opinion / consensus documents) highlighted the necessity to make simpler this clinical pathway. Our paper illustrates the cost of this pathway incurred by patients (direct healthcare and non-healthcare costs, productivity losses by patients and their possible care-giver due to the time dedicated to healthcare services).

Methods. The study relied on a retrospective data collection through a structured questionnaire administered to 240 patients, being on treatments with PCSK9-inhibitor drugs for at least one year. Patients were recruited in 4 Italian healthcare centres from June 2020 to July 2021.

Results. Recruited patients are 64 years old on average. 64% of patients are males and 36% are actively employed and working. Mean cost incurred by patients amounts to € 926,1. Direct healthcare costs, direct non-healthcare costs and productivity losses equal to € 463,5 (50%), € 136,7 (15%) and € 325,9 (35%) respectively. Healthcare services fully covered by the National Health Service account for 56% of the total. Co-payments are applied to 26% of healthcare services, whereas patients pay the full price for 18% healthcare services.

Discussion. Getting eligibility to PCSK9-inhibitors and managing patients’ follow-up generate important costs incurred by patients. Furthermore, these costs are very different across healthcare centres. We are fully aware that appropriateness of prescriptions and patients’ follow-up are very important. However, simplifying the clinical pathway would bring economic advantages and could make more homogenous the way this pathway is managed by healthcare centres.

Downloads

Download data is not yet available.

References

AIFA. (CTS) – Ordine del Giorno 47 della Riunione Straordinaria del 24 maggio 2021 (Accessed April 22, 2022) https://www.aifa.gov.it/documents/20142/1508177/OdG_generale_CTS_straordinaria_del_24_maggio_2021.pdf.

Cortese B, Di Palma G, Lettieri C, Musumeci G. Inibitori di PCSK9: il difficile connubio fra evidenze scientifiche e limitazioni regolatorie. G Ital Cardiol (Rome). 2018;19(2):77-80. PMID:29531379

Jommi C, Cavazza M. Management of patients eligible to PCSK-9 Inhibitors: economic impact and reform proposals. Glob Reg Health Technol Assess. 2019;6:1-12. https://doi.org/10.33393/grhta.2019.460 DOI: https://doi.org/10.1177/2284240319861375

Kaufman TM, Warden BA, Minnier J, et al. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019;124(1):32-37. https://doi.org/10.1161/CIRCRESAHA.118.314191 PMID:30605414 DOI: https://doi.org/10.1161/CIRCRESAHA.118.314191

Bagepally BS, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. Eur J Clin Pharmacol. 2022;78(3):351-363. https://doi.org/10.1007/s00228-021-03242-6 PMID:34708270 DOI: https://doi.org/10.1007/s00228-021-03242-6

Lohr S. Sampling: Design and Analysis. 2nd ed. Brooks/Cole; 2010.

Banca d’Italia. Indagine sui bilanci delle famiglie italiane nell’anno 2016 (Accessed March 03, 2022) (https://www.bancaditalia.it/pubblicazioni/indagine-famiglie/bil-fam2016/index.html).

ISTAT – Prezzi al consumo 2020 (Accessed March 03, 2022) (https://www.istat.it/it/archivio/252604).

Published

2022-07-18

How to Cite

Bertolani, A., Ravasio, R., Raimondo, P., & Jommi, C. (2022). The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study. Global and Regional Health Technology Assessment, 9(1), 73–81. https://doi.org/10.33393/grhta.2022.2415

Issue

Section

Original Research Articles

Categories

Received 2022-05-03
Accepted 2022-07-05
Published 2022-07-18

Metrics

Most read articles by the same author(s)

1 2 3 4 5 6 > >>